{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}],"title":"Grade 2 Nausea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}],"title":"Grade 2 Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"}]}],"title":"Grade 2 Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"Grade 3 Insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}],"title":"Grade 2 Anxiety"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}],"title":"Grade 2 Agitation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"168"},{"groupId":"OG001","value":"169"}],"units":"Participants"}],"description":"Adverse events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grading: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening, Grade 5=Death.","groups":[{"description":"Patients received oral American ginseng twice daily for 14 days. This treatment was repeated every two weeks for 4 courses, for a total of 8 weeks of treatment.","id":"OG000","title":"Ginseng"},{"description":"Patients received oral placebo twice daily for 14 days. This treatment was repeated every two weeks for 4 courses, for a total of 8 weeks of treatment..","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Includes all participants that reported at least one value after baseline.","reportingStatus":"POSTED","timeFrame":"Week 1 to Week 8","title":"Number of Treatment Related Grade 2 to 3 Adverse Events >=1% Incidence","type":"SECONDARY","unitOfMeasure":"participants"}